188 related articles for article (PubMed ID: 10845390)
1. Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas.
Rushing EJ; Colvin SM; Gazdar A; Miura N; White CL; Coimbra C; Burns DK
J Neurooncol; 1999; 45(3):199-207. PubMed ID: 10845390
[TBL] [Abstract][Full Text] [Related]
2. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
3. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
4. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 staining index of pediatric meningiomas.
Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
[TBL] [Abstract][Full Text] [Related]
6. Proliferation and DNA fragmentation in meningioma subtypes.
Maier H; Wanschitz J; Sedivy R; Rössler K; Ofner D; Budka H
Neuropathol Appl Neurobiol; 1997 Dec; 23(6):496-506. PubMed ID: 9460716
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo.
Cabuy E; de Ridder L
Virchows Arch; 2001 Aug; 439(2):176-84. PubMed ID: 11561758
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
12. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
13. Meningiomas: correlation of Ki67 with histological grade.
Babu S; Uppin SG; Uppin MS; Panigrahi MK; Saradhi V; Bhattacharjee S; Sahu BP; Purohit AK; Challa S
Neurol India; 2011; 59(2):204-7. PubMed ID: 21483118
[TBL] [Abstract][Full Text] [Related]
14. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
[TBL] [Abstract][Full Text] [Related]
15. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
17. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
19. Recurrent and atypical meningiomas--a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining.
Ferraraccio F; Accardo M; Giangaspero F; Cuccurullo L
Clin Neuropathol; 2003; 22(4):187-92. PubMed ID: 12908755
[TBL] [Abstract][Full Text] [Related]
20. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]